keyword
MENU ▼
Read by QxMD icon Read
search

Benicar

keyword
https://www.readbyqxmd.com/read/24672214/olmesartan-and-drug-induced-enteropathy
#1
Tran H Tran, Hanlin Li
In three case histories, patients' sprue-like symptoms improved when olmesartan (Benicar) therapy was withheld.
January 2014: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/22920048/efficacy-of-olmesartan-medoxomil-and-hydrochlorothiazide-fixed-dose-combination-therapy-in-patients-aged-65-years-and-older-with-stage-1-and-2-hypertension-or-isolated-systolic-hypertension
#2
MULTICENTER STUDY
F Wilford Germino, Joel M Neutel, Robert Dubiel, Jen-Fue Maa, Kathleen J Chavanu
BACKGROUND: The incidence of hypertension, particularly isolated systolic hypertension, increases with increasing age, as does the risk of fatal cardiovascular disease. A combination antihypertensive therapy regimen may be required to reach recommended BP goals in older patients. OBJECTIVES: This study set out to report blood pressure (BP) data in elderly patients across the subgroups of stage 1 and stage 2 hypertension (prespecified subgroup) and isolated systolic hypertension (ISH) [post hoc]...
October 1, 2012: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://www.readbyqxmd.com/read/20814402/tribenzor-for-hypertension
#3
(no author information available yet)
Many patients with hypertension require more than one drug to control their blood pressure.1 Tribenzor (Daiichi Sankyo), recently approved by the FDA for treatment of hypertension, combines the calcium channel blocker amlodipine (Norvasc, and others), the angiotensin receptor blocker (ARB) olmesartan (Benicar) and the most commonly prescribed diuretic, hydrochlorothiazide (HCTZ). Tribenzor is not approved for initial therapy, but is recommended for patients not adequately controlled on any 2-drug combination of a calcium channel blocker, an ARB or a diuretic...
September 6, 2010: Medical Letter on Drugs and Therapeutics
https://www.readbyqxmd.com/read/20085534/effects-of-an-olmesartan-medoxomil-based-treatment-algorithm-on-24-hour-blood-pressure-control-in-patients-with-hypertension-and-type-2-diabetes
#4
RANDOMIZED CONTROLLED TRIAL
Joel M Neutel, Dean J Kereiakes, William F Waverczak, Kathy A Stoakes, Jianbo Xu, Ali Shojaee
OBJECTIVE: The BENIFICIARY (BENIcar safety and efFICacy evaluatIon: An open-label, single-ARm, titration study in patients with hypertension and tYpe 2 diabetes) study was conducted to evaluate the efficacy and safety of olmesartan medoxomil (OM) plus hydrochlorothiazide (HCTZ) in patients with hypertension and type 2 diabetes. RESEARCH DESIGN AND METHODS: After a placebo run-in period, 192 patients received OM 20 mg/day for 3 weeks. If blood pressure (BP) remained > or =120/70 mm Hg, patients were up-titrated to OM 40 mg/day for 3 weeks and subsequently (in 3-week intervals) to OM/HCTZ 40/12...
March 2010: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/19645202/did-dr-nurse-fail-notify-pregnant-pt-to-d-c-benicar-mobile-ob-gyn-pc-v-baggett-2009-al-0615-006-6-12-2009-al
#5
(no author information available yet)
No abstract text is available yet for this article.
June 2009: Nursing Law's Regan Report
https://www.readbyqxmd.com/read/18547134/olmesartan-medoxomil-a-review-of-its-use-in-the-management-of-hypertension
#6
REVIEW
Lesley J Scott, Paul L McCormack
Olmesartan medoxomil (Olmetec, Benicar) is an angiotensin II type 1 (AT(1)) receptor antagonist (angiotensin receptor blocker [ARB]) that inhibits the actions of angiotensin II on the renin-angiotensin-aldosterone system, which plays a key role in the pathogenesis of hypertension. Oral olmesartan medoxomil 10-40 mg once daily is recommended for the treatment of adult patients with hypertension. In those with inadequate BP control using monotherapy, fixed-dose olmesartan medoxomil/hydrochlorothiazide (HCTZ) [Olmetec plus, Benicar-HCT] combination therapy may be initiated...
2008: Drugs
https://www.readbyqxmd.com/read/15631537/use-of-24-hour-ambulatory-blood-pressure-monitoring-to-assess-antihypertensive-efficacy-a-comparison-of-olmesartan-medoxomil-losartan-potassium-valsartan-and-irbesartan
#7
RANDOMIZED CONTROLLED TRIAL
David H G Smith, Robert Dubiel, Michael Jones
INTRODUCTION: Goal rates, the percentage of patients with hypertension achieving recommended SBP/DBP, are a clinically important assessment of an antihypertensive agent's efficacy. Twenty-four-hour ambulatory blood pressure monitoring (ABPM) allows accurate assessment of a patient's hypertension and risk for cardiovascular events, and provides the most accurate measure of an antihypertensive agent's efficacy throughout a 24-hour dosing interval. METHODS: A 12-week (4-week single-blind placebo run-in phase followed by an 8-week double-blind active treatment phase) randomized, parallel-group study reported that the recommended starting dose of the angiotensin II receptor antagonist (angiotensin receptor blocker; ARB) olmesartan medoxomil (Benicar(trade mark)) 20 mg/day was more effective than starting doses of losartan potassium (Cozaar) 50 mg/day, valsartan (Diovan) 80 mg/day, or irbesartan (Avapro) 150 mg/day in reducing cuff DBP in patients with essential hypertension...
2005: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://www.readbyqxmd.com/read/12503943/olmesartan-medoxomil-the-seventh-angiotensin-receptor-antagonist
#8
REVIEW
Stephanie F Gardner, Amy M Franks
OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, and adverse effects of olmesartan medoxomil, an angiotensin II receptor antagonist for the treatment of hypertension. DATA SOURCES: Information was obtained from MEDLINE searches (1996-April 2002) of English-language medical literature. Search terms included CS-866, olmesartan, olmesartan medoxomil, RNH-6270 (active metabolite of olmesartan), Benicar, angiotensin receptors, and antihypertensive agents...
January 2003: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/12163839/olmesartan-benicar-for-hypertension
#9
(no author information available yet)
No abstract text is available yet for this article.
August 5, 2002: Medical Letter on Drugs and Therapeutics
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"